Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 α-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies-Part 1.

Literature DB >> 29545378

α-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies-Part 1.

Sophie Poty¹, Lynn C Francesconi^2,3, Michael R McDevitt^1,4, Michael J Morris⁵, Jason S Lewis^6,7.

Abstract

With a short particle range and high linear energy transfer, α-emitting radionuclides demonstrate high cell-killing efficiencies. Even with the existence of numerous radionuclides that decay by α-particle emission, only a few of these can reasonably be exploited for therapeutic purposes. Factors including radioisotope availability and physical characteristics (e.g., half-life) can limit their widespread dissemination. The first part of this review will explore the diversity, basic radiochemistry, restrictions, and hurdles of α-emitters.

Keywords: clinical trials; radiochemistry; radiotherapy; α-emitters

Mesh：

Year: 2018 PMID： 29545378 PMCID： PMC6004557 DOI： 10.2967/jnumed.116.186338

Source DB: PubMed Journal: J Nucl Med ISSN： 0161-5505 Impact factor: 10.057

54 in total

1. Survival of human lung epithelial cells following in vitro alpha-particle irradiation with absolute determination of the number of alpha-particle traversals of individual cells.

Authors: C Søyland; S P Hassfjell
Journal: Int J Radiat Biol Date: 2000-10 Impact factor: 2.694

2. A 212Pb generator based on a 228Th source.

Authors: S Hassfjell
Journal: Appl Radiat Isot Date: 2001-10 Impact factor: 1.513

3. Malignant transformation of human benign prostate epithelial cells by high linear energy transfer alpha-particles.

Authors: Hongzhen Li; Yongpeng Gu; Jun Miki; Bharati Hukku; David G McLeod; Tom K Hei; Johng S Rhim
Journal: Int J Oncol Date: 2007-09 Impact factor: 5.650

4. Treatment of solid tumors by interstitial release of recoiling short-lived alpha emitters.

Authors: L Arazi; T Cooks; M Schmidt; Y Keisari; I Kelson
Journal: Phys Med Biol Date: 2007-08-01 Impact factor: 3.609

5. Phase I pharmacokinetic and biodistribution study with escalating doses of ²²³Ra-dichloride in men with castration-resistant metastatic prostate cancer.

Authors: Jorge A Carrasquillo; Joseph A O'Donoghue; Neeta Pandit-Taskar; John L Humm; Dana E Rathkopf; Susan F Slovin; Matthew J Williamson; Kristine Lacuna; Anne-Kirsti Aksnes; Steven M Larson; Howard I Scher; Michael J Morris
Journal: Eur J Nucl Med Mol Imaging Date: 2013-05-08 Impact factor: 9.236

6. Comparison of 211At-PRIT and 211At-RIT of ovarian microtumors in a nude mouse model.

Authors: Sofia H L Frost; Tom Bäck; Nicolas Chouin; Ragnar Hultborn; Lars Jacobsson; Jörgen Elgqvist; Holger Jensen; Per Albertsson; Sture Lindegren
Journal: Cancer Biother Radiopharm Date: 2012-12-11 Impact factor: 3.099

Review 7. Avidin-biotin technology in targeted therapy.

Authors: Hanna P Lesch; Minna U Kaikkonen; Jere T Pikkarainen; Seppo Ylä-Herttuala
Journal: Expert Opin Drug Deliv Date: 2010-05 Impact factor: 6.648

8. Large scale accelerator production of ²²⁵Ac: Effective cross sections for 78-192MeV protons incident on ²³²Th targets.

Authors: J R Griswold; D G Medvedev; J W Engle; R Copping; J M Fitzsimmons; V Radchenko; J C Cooley; M E Fassbender; D L Denton; K E Murphy; A C Owens; E R Birnbaum; K D John; F M Nortier; D W Stracener; L H Heilbronn; L F Mausner; S Mirzadeh
Journal: Appl Radiat Isot Date: 2016-09-28 Impact factor: 1.513

Review 9. Production of [(211)At]-astatinated radiopharmaceuticals and applications in targeted α-particle therapy.

Authors: François Guérard; Jean-François Gestin; Martin W Brechbiel
Journal: Cancer Biother Radiopharm Date: 2012-10-17 Impact factor: 3.099

Review 10. A Critical Review of Alpha Radionuclide Therapy-How to Deal with Recoiling Daughters?

Authors: Robin M de Kruijff; Hubert T Wolterbeek; Antonia G Denkova
Journal: Pharmaceuticals (Basel) Date: 2015-06-10

30 in total

1. Value proposition of PSMA-targeted α-particle radioligand therapy in metastatic prostate cancer.

Authors: Hossein Jadvar
Journal: Eur J Nucl Med Mol Imaging Date: 2018-10-11 Impact factor: 9.236

2. Leveraging Bioorthogonal Click Chemistry to Improve ²²⁵Ac-Radioimmunotherapy of Pancreatic Ductal Adenocarcinoma.

Authors: Sophie Poty; Lukas M Carter; Komal Mandleywala; Rosemery Membreno; Dalya Abdel-Atti; Ashwin Ragupathi; Wolfgang W Scholz; Brian M Zeglis; Jason S Lewis
Journal: Clin Cancer Res Date: 2018-10-23 Impact factor: 12.531

Review 3. Imaging for Response Assessment in Cancer Clinical Trials.

Authors: Anna G Sorace; Asser A Elkassem; Samuel J Galgano; Suzanne E Lapi; Benjamin M Larimer; Savannah C Partridge; C Chad Quarles; Kirsten Reeves; Tiara S Napier; Patrick N Song; Thomas E Yankeelov; Stefanie Woodard; Andrew D Smith
Journal: Semin Nucl Med Date: 2020-06-10 Impact factor: 4.446

4. Targeted α-Therapy in Cancer Management: Synopsis of Preclinical and Clinical Studies.

Authors: Hossein Jadvar
Journal: Cancer Biother Radiopharm Date: 2020-03-23 Impact factor: 3.099

Review 5. Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The "Hopeful Eight".

Authors: Romain Eychenne; Michel Chérel; Férid Haddad; François Guérard; Jean-François Gestin
Journal: Pharmaceutics Date: 2021-06-18 Impact factor: 6.321

6. Cellular and Genetic Determinants of the Sensitivity of Cancer to α-Particle Irradiation.

Authors: Brian D Yard; Priyanka Gopal; Kristina Bannik; Gerhard Siemeister; Urs B Hagemann; Mohamed E Abazeed
Journal: Cancer Res Date: 2019-08-06 Impact factor: 12.701

7. Synthesis and preliminary evaluation of ²¹¹At-labeled inhibitors of prostate-specific membrane antigen for targeted alpha particle therapy of prostate cancer.

Authors: Ganesan Vaidyanathan; Ronnie C Mease; Il Minn; Jaeyeon Choi; Ying Chen; Hassan Shallal; Choong Mo Kang; Darryl McDougald; Vivek Kumar; Martin G Pomper; Michael R Zalutsky
Journal: Nucl Med Biol Date: 2021-01-23 Impact factor: 2.408

α-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies-Part 1.

1. Survival of human lung epithelial cells following in vitro alpha-particle irradiation with absolute determination of the number of alpha-particle traversals of individual cells.

2. A 212Pb generator based on a 228Th source.

3. Malignant transformation of human benign prostate epithelial cells by high linear energy transfer alpha-particles.

4. Treatment of solid tumors by interstitial release of recoiling short-lived alpha emitters.

5. Phase I pharmacokinetic and biodistribution study with escalating doses of ²²³Ra-dichloride in men with castration-resistant metastatic prostate cancer.

6. Comparison of 211At-PRIT and 211At-RIT of ovarian microtumors in a nude mouse model.

Review 7. Avidin-biotin technology in targeted therapy.

8. Large scale accelerator production of ²²⁵Ac: Effective cross sections for 78-192MeV protons incident on ²³²Th targets.

Review 9. Production of [(211)At]-astatinated radiopharmaceuticals and applications in targeted α-particle therapy.

Review 10. A Critical Review of Alpha Radionuclide Therapy-How to Deal with Recoiling Daughters?

1. Value proposition of PSMA-targeted α-particle radioligand therapy in metastatic prostate cancer.

2. Leveraging Bioorthogonal Click Chemistry to Improve ²²⁵Ac-Radioimmunotherapy of Pancreatic Ductal Adenocarcinoma.

Review 3. Imaging for Response Assessment in Cancer Clinical Trials.

4. Targeted α-Therapy in Cancer Management: Synopsis of Preclinical and Clinical Studies.

Review 5. Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The "Hopeful Eight".

6. Cellular and Genetic Determinants of the Sensitivity of Cancer to α-Particle Irradiation.

7. Synthesis and preliminary evaluation of ²¹¹At-labeled inhibitors of prostate-specific membrane antigen for targeted alpha particle therapy of prostate cancer.

Review 8. Targeted α-therapy in non-prostate malignancies.

Review 9. Perspectives on metals-based radioimmunotherapy (RIT): moving forward.

Review 10. Production, purification and availability of ²¹¹At: Near term steps towards global access.

Review 7. Avidin-biotin technology in targeted therapy.

Review 9. Production of [(211)At]-astatinated radiopharmaceuticals and applications in targeted α-particle therapy.

Review 10. A Critical Review of Alpha Radionuclide Therapy-How to Deal with Recoiling Daughters?

Review 3. Imaging for Response Assessment in Cancer Clinical Trials.

Review 5. Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The "Hopeful Eight".

Review 8. Targeted α-therapy in non-prostate malignancies.

Review 9. Perspectives on metals-based radioimmunotherapy (RIT): moving forward.

Review 10. Production, purification and availability of 211At: Near term steps towards global access.

Review 10. Production, purification and availability of ²¹¹At: Near term steps towards global access.